Nutex Health (NUTX) has drawn fresh attention after amending its agreement with HaloMD to a pay as you go model, aligning with No Surprises Act rules as investors watch upcoming quarterly results.

Nutex Health’s recent shift to a pay as you go model with HaloMD comes as the stock experiences mixed momentum, with the share price down 6.57% over one day and 10.68% over seven days, but up 4.69% over 30 days and 43.83% over 90 days, alongside a 69.23% 1 year total shareholder return and 163.86% 3 year total shareholder return that highlight how sentiment and risk perceptions around the company have evolved over time.

If this kind of regulatory and earnings driven story has your attention, it could be a good moment to see what else is moving through the healthcare space with 41 healthcare AI stocks

After a sharp swing in Nutex Health’s share price and a shift to pay-as-you-go fees that could reshape cash flow, the next step is clear: does the current valuation still leave more upside for new buyers than downside risk?

Most Popular Narrative: 33.2% Undervalued

Against Nutex Health’s last close of $157.21, the most followed narrative anchors on a fair value of $235.50, framed through a detailed earnings and margin trajectory discounted at 7.21%.

The company's successful navigation of value-based care and risk-based contracts, including rapid expansion of IPAs and population health management capabilities, positions it to benefit from industry reimbursement trends, potentially boosting margins and recurring earnings as the model matures.

Cost discipline through vertical integration with physician groups, lean operations, and prospective tech investments (AI-driven workflows, health IT) are described as driving improved gross and EBITDA margins (for example, G&A reported at 4.9% of revenue). These factors are presented as potential contributors to net margin expansion and earnings growth with increased scale.

Want the full story behind that $235.50 fair value for Nutex Health? The narrative centers on a mix of recurring earnings, higher margins and a future profit multiple that is modeled as different from today. Curious which financial levers carry most of the weight in that model and how they are projected to stack across the next few years? The detailed assumptions sit just beneath the headline target.

Result: Fair Value of $235.50 (UNDERVALUED)

However, this Nutex Health narrative still leans heavily on arbitration related revenue and assumes smoother execution on reporting and controls, both of which could unsettle confidence if they break.

Another View on Nutex Health’s Valuation

That 33.2% undervalued fair value for Nutex Health is built on detailed earnings and margin paths, but our DCF model points the other way, with an estimate of $16.31 per share. This would frame the current $157.21 price as very expensive and raise questions about how much optimism is already in the stock.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nutex Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Nutex Health’s story pulling in both enthusiasm and caution, now is a good time to review the data yourself and decide where you stand. To weigh the key concerns against the potential upsides side by side, start with the 4 key rewards and 3 important warning signs.

Looking for more Nutex Health style investment ideas?

If Nutex Health has sharpened your focus, do not stop here. Broaden your watchlist with a few focused stock ideas that other investors are already tracking closely.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive pricing using the 47 high quality undervalued stocks.
• Strengthen your income stream by hunting for companies with higher yields and resilient payout histories through the 7 dividend fortresses.
• Reduce portfolio stress by filtering for companies that show steadier risk profiles and financial resilience via the 82 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.